2 Great Stocks to Buy in 2026 Down 50% and 80% from their Highs

The piece highlights two S&P 500 stocks — Deckers (DECK) and Align Technology (ALGN) — as beaten-down, high-upside opportunities after steep pullbacks (DECK ~53% below Jan 2025 highs; ALGN ~80% off peak). Deckers, with ~$1.4B cash, $3.8B assets vs $1.3B liabilities and zero debt, posted average revenue growth of ~19% and GAAP EPS growth of 32% from FY21–FY25, is projected to grow revenue ~8% in FY26 (EPS +1%) and trades at ~15.4X forward earnings; Align trades near 18X forward earnings, holds ~$1B cash and $6.2B assets vs $2.3B liabilities, saw Clear Aligner volume +4.9% YoY in Q3 and is forecast to grow adjusted EPS ~9% in 2025 and ~7% in 2026. Both names are presented as fundamentally strong, non-AI plays with solid balance sheets, favorable analyst revisions (Zacks Rank #2 for DECK) and technical setups that could attract buyers if execution normalizes.

Analysis

Market structure: The immediate beneficiaries are niche premium footwear makers (DECK, ONON) and vertically integrated DTC models that preserve margin; losers include legacy volume players (NKE) and lower-end footwear retail that compete on price. Inventory normalization and continued brand-led share shifts will tighten demand for HOKA-like SKUs while input-cost volatility (rubber, synthetic textiles, freight) keeps gross-margin dispersion wide. Cross-asset: a durable consumer slowdown would push IG spreads wider and steepen FX sensitivity (USD up compresses emerging revenue); options IV for cyclical names should remain elevated into earnings windows.

Risk assessment: Tail risks — a consumer spending shock (GDP contraction >1% annualized), renewed tariffs on China footwear, or a regulatory bite into orthodontic device reimbursement — could wipe 30–50% off current levels quickly. Near-term (0–3 months) risk centers on FY26 guidance and inventory commentary; medium (3–12 months) on promotional cycles; long (12–36 months) on secular share gains or loss of brand desirability. Hidden dependencies: DECK’s growth concentrated in HOKA and DTC mix; ALGN dependent on clinician adoption and teen volume recovery.

Trade implications: Tactical direct plays: establish a core long in DECK (2–3% portfolio) sized to a 12–24 month horizon, scaling in 60% at current levels and 40% on a 15% pullback; cap downside with a -20% stop or buy a protective put. For ALGN, initate a smaller core (1–2%) via a 12-month call spread to limit capital at risk while keeping upside to a normalization scenario; run a pair trade long DECK vs short NKE equal notional to express share-shift thesis. Sell 3-month cash-secured puts ~15% OTM on DECK to enhance yield; use earnings windows to trim into strength.

Contrarian angles: The market may be over-discounting permanent loss of demand — DECK at 15.4x forward and ALGN at ~18x forward trade well below long-term medians, implying multi-quarter structural collapse rather than cyclical normalization. Historical parallels: post-COVID pullforwards in elective healthcare and athleisure show V-shaped recoveries once out-of-stock and promotional noise clear (6–18 months). Unintended consequence: a broad AI-tech correction could reallocate flows to tangible consumer/healthcare performers and catalyze a rapid re-rating; conversely, a macro shock would punish both deeply — size positions accordingly.

Key Decisions for Investors

• Establish a core long position in DECK equal to 2–3% of portfolio capital, scale 60% now and 40% on a 10–15% pullback; target +100–115% over 12–24 months, set tactical stop-loss at -20% from average cost or hedge with a 6–9 month protective put (10–15% OTM).
• Initiate a smaller, hedged exposure to ALGN (1–2% portfolio) via a 12-month call spread (buy near-the-money call, sell 30–50% OTM call) to cap downside while allowing >50% upside if volumes normalize by 2026–2028; reassess after next two quarterly volume prints.
• Implement a relative-value pair: long DECK / short NKE equal-dollar exposure (1–1.5% net each) to express HOKA share gains versus legacy volume pressure; rebalance if DECK outperforms by >30% or NKE outperforms by >20%.
• Write 3-month cash-secured puts on DECK ~15% OTM to collect premium and potentially acquire stock at a lower basis; size notional to commit no more than the intended core allocation.
• Reduce concentrated exposure to large-cap AI/mega-cap growth by 3–5% and rotate proceeds into selective consumer discretionary (DECK) and medical-tech recovery (ALGN) trades, monitoring: DECK FY26 guide, ALGN clinician order trends, and US consumer discretionary retail sales (monthly) for re-rating triggers.